Heavy Metal Poisoning Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

Heavy Metal Poisoning Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com




Heavy Metal Poisoning Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Heavy Metal Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

The guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)

     

Key Topics Covered:

Report Coverage

  • Overview
  • Therapeutics Development

Pipeline Overview

  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Heavy Metal Poisoning – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heavy Metal Poisoning – Companies Involved in Therapeutics Development

Medesis Pharma SA

PDX Pharmaceuticals LLC

ZoneOne Pharma Inc

Heavy Metal Poisoning – Drug Profiles

deferoxamine mesylate – Drug Profile

hinokitiol – Drug Profile

NU-02 – Drug Profile

PDX-003 – Drug Profile

Small Molecule for Heavy Metal Poisoning – Drug Profile

  • Heavy Metal Poisoning – Dormant Projects
  • Heavy Metal Poisoning – Discontinued Products
  • Heavy Metal Poisoning – Product Development Milestones

Companies Mentioned

  • Medesis Pharma SA
  • PDX Pharmaceuticals LLC
  • ZoneOne Pharma Inc

For more information about this report visit https://www.researchandmarkets.com/r/mn71nu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900